Latanoprostene bunod
 | |
| Clinical data | |
|---|---|
| Trade names | Vyzulta |
| Other names | BOL-303259-X |
| AHFS/Drugs.com | Monograph |
| License data | |
| Drug class | Prostaglandin analog |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.251.571 |
| Chemical and physical data | |
| Formula | C27H41NO8 |
| Molar mass | 507.624 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Latanoprostene bunod, sold under the brand name Vyzulta, is an ophthalmic medication used for the reduction of intraocular pressure in people with open-angle glaucoma or ocular hypertension.[2][3] It targets the trabecular meshwork directly.[3] It is a prostaglandin analog.[2]
The most common side effects include conjunctival (eye) redness, eye irritation, and eye discomfort (pain).[4] Latanoprostene bunod may cause the iris (colored part of the eye) to become darker in color.[4]
Latanoprostene bunod was approved for medical use in the United States in November 2017.[2][4][5]
Medical uses
[edit]Latanoprostene bunod is indicated for the reduction of intraocular pressure in people with open-angle glaucoma or ocular hypertension.[2]
History
[edit]The US Food and Drug Administration (FDA) approved latanoprostene bunod based on evidence from two clinical trials that enrolled 840 participants with open angle glaucoma or ocular hypertension.[4] The trials evaluated the benefits and side effects of latanoprostene bunod.[4] In each trial, participants were randomly assigned to receive either latanoprostene bunod or an approved drug timolol (ophthalmic solution) every day for three months.[4] Neither the participants nor the health care providers knew which treatment was being given until after the trials were completed.[4] The trials were conducted in the United States, the United Kingdom, Germany, Italy, Bulgaria, the Czech Republic, and Japan.[4]
References
[edit]- ^ "Regulatory Decision Summary for Vyzulta". Health Canada. 27 December 2018.
- ^ a b c d e "Vyzulta- latanoprostene bunod solution/ drops". DailyMed. 1 May 2019. Archived from the original on 7 June 2022. Retrieved 7 June 2022.
- ^ a b Hoy SM (May 2018). "Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension". Drugs. 78 (7): 773–780. doi:10.1007/s40265-018-0914-6. PMC 5976683. PMID 29761382.
- ^ a b c d e f g h "Vyzulta". U.S. Food and Drug Administration (FDA). 2 November 2017. Archived from the original on 11 July 2024. Retrieved 11 July 2024.
This article incorporates text from this source, which is in the public domain.
- ^ "Bausch + Lomb And Nicox Announce FDA Approval Of Vyzulta (Latanoprostene Bunod Ophthalmic Solution), 0.024%" (Press release). Valeant Pharmaceuticals. 2 November 2017. Archived from the original on 11 July 2024. Retrieved 11 July 2024 – via PR Newswire.
